Abstract 1668P
Background
Significant progress has been made in the management of PDAC in recent years, with the development of new chemotherapy regimens validated in both adjuvant and metastatic settings, as well as neoadjuvant/induction therapy (N/IT). In this population-based study, we aimed to compare prevalence, therapeutic strategies, and survival outcomes of PDAC patients in France over a decade encompassing these advances.
Methods
This study was performed on SNDS (Système National des Données de Santé) data, including nationwide French data on the consumption of medical care. All patients managed for PDAC during years 2009, 2014 and 2018 were included. Treatment modalities and survival outcomes were analyzed.
Results
A total of 8143/10267/12089 patients were included during years 2009/2014/2018, respectively. Prevalence increased mainly among patients aged 60-75 (62% over the study period) and >75 (53%) while a lesser trend was seen in patients <60 (13%). In localized PDAC, the proportion of patients receiving best supportive care (BSC) decreased at 43.6/37.7/33.5%. More patients received chemotherapy +/- radiotherapy alone over time (27.8/28.5/33.4%), and surgical resection after N/IT increased at 0.9/2.5/5.5%. The rate of upfront surgery remained stable at about 28%. Among metastatic patients, 45.0/49.2/51.3% received BSC. In the overall population, no relevant difference in survival outcomes were seen over time, but median overall survival (OS) and 1-year OS improved significantly both in localized patients and treated metastatic patients (Table). The 1-year OS was 85.7/85.9/91.7% among patients receiving N/IT before surgery, vs 76.3/79.0/80.0% for upfront resection. Table: 1668P
Survival outcomes
Population | Median OS (months) / 1-year OS (%) | p-value log-rank | ||
2009 | 2014 | 2018 | ||
Overall | 7.0 / 36.1 | 6.9 / 36.9 | 7.5 / 39.4 | 0.0067 |
Localized | 11.4 / 48.4 | 12.5 / 51.3 | Not reached / 55.0 | <0.0001 |
Metastatic (treated) | 7.3 / 30.3 | 8.4 / 36.1 | 8.9 / 38.2 | <0.0001 |
Conclusions
This study confirms an increase in the prevalence of PDAC in France. Improved survival outcomes were seen in localized PDAC, with a wider use of chemotherapy and an increase in neo-adjuvant/induction strategies, and in treated metastatic patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ACOBIOM.
Funding
ACOBIOM.
Disclosure
L. Mas: Financial Interests, Personal, financially compensated role: Merck. J. Bachet: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bayer, BMS, GSK, Merck, MSD, Pierre Fabre, Roche, Sanofi, Servier; Financial Interests, Personal, Non-financial benefits: Amgen, Merck, Roche, Servier. All other authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22